Patents by Inventor Nuria Izquierdo Useros

Nuria Izquierdo Useros has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LERIGLITAZONE FOR TREATING LUNG INFLAMMATION AND INTERSTITIAL LUNG DISEASE
    Publication number: 20230172921
    Abstract: The present disclosure provides methods of treating viral-induced inflammatory lung conditions or diseases, acute inflammation of the lung, or interstitial lung disease with 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione, or a pharmaceutically acceptable salt thereof, or 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 30, 2021
    Publication date: June 8, 2023
    Applicant: Minoryx Therapeutics S.L.
    Inventors: Marc MARTINELL PEDEMONTE, Maria Pilar PIZCUETA LALANZA, Anna VILALTA SAURA, Estefania TRAVER LÓPEZ, Sonia Maria POLI, Nuria IZQUIERDO USEROS
  • ANTIVIRAL AND ANTIBACTERIAL COMPOSITION
    Publication number: 20230157297
    Abstract: The use of a composition as antiviral and/or antimicrobial agent, wherein the composition includes at least a positively charged natural or unnatural amino acid, an organic acid, a cationic polymer and a zwitterionic surfactant.
    Type: Application
    Filed: April 22, 2021
    Publication date: May 25, 2023
    Applicant: Cedar Advanced Technology Group Ltd.
    Inventors: Said FARHA, Kamal FARHA, Gerald A. HUTCHINSON, Bradley J. NELSON, Salvador PANÉ VIDAL, Alexei ERMAKOV, Carlos FRANCO PUJANTE, Nuria IZQUIERDO USEROS, Julian BLANCO ARBUES
  • PLD FOR USE IN COMBINATION IN THE TREATMENT OF CORONAVIRUS
    Publication number: 20230158103
    Abstract: The use of PLD with one or more further CoV antiviral agent(s) in the treatment of coronavirus (CoV) infection.
    Type: Application
    Filed: March 2, 2021
    Publication date: May 25, 2023
    Inventors: Nuria IZQUIERDO-USEROS, Júlia VERGARA-ALERT, Pablo AVILÉS MARÍN, Alejandro LOSADA GONZÁLEZ, José María FERNÁNDEZ SOUSA-FARO, Salvador FUDIO MUÑOZ
  • Method for blocking HIV entry into dendritic cells by inhibiting sialoadhesin-sialyllactose binding interactions with gangliosides
    Patent number: 9789130
    Abstract: The present invention refers to methods and compositions to prevent viral entry into cells expressing the CD169/sialoadhesin surface receptor by inhibiting the coupling of the sialyllactose molecule contained in the viral membrane gangliosides to the CD 169/sialoadhesin receptor. The invention also pertains to vaccine compositions based on dendritic cells loaded with an antigen of interest whereby the vaccine is provided together with a composition capable of preventing viral entry into cells expressing the CD169/sialoadhesin. Moreover, the invention relates to diagnostic and therapeutic compositions that can be specifically delivered to enveloped virions wherein the diagnostic/therapeutic agent is coupled to CD169/sialoadhesin.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: October 17, 2017
    Assignees: LABORATORIOS DEL DR. ESTEVE, S.A., FUNDACIÓ PRIVADA INSTITUT DE RECERCA DE LA SIDA—CAIXA, INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS, RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
    Inventors: Nuria Izquierdo Useros, Hans-Georg Krauesslich, Maier Lorizate, Javier Martinez Picado
  • INHIBITORS OF SIALOADHESIN FOR THE TREATMENT OF DISEASES CAUSED BY ENVELOPED VIRUSES
    Publication number: 20140370052
    Abstract: The present invention refers to methods and compositions to prevent viral entry into cells expressing the CD169/sialoadhesin surface receptor by inhibiting the coupling of the sialyllactose molecule contained in the viral membrane gangliosides to the CD 169/sialoadhesin receptor. The invention also pertains to vaccine compositions based on dendritic cells loaded with an antigen of interest whereby the vaccine is provided together with a composition capable of preventing viral entry into cells expressing the CD169/sialoadhesin. Moreover, the invention relates to diagnostic and therapeutic compositions that can be specifically delivered to enveloped virions wherein the diagnostic/therapeutic agent is coupled to CD169/sialoadhesin.
    Type: Application
    Filed: December 17, 2012
    Publication date: December 18, 2014
    Inventors: Nuria Izquierdo Useros, Hans-Georg Krauesslich, Maier Lorizate, Javier Martinez Picado